<DOC>
	<DOCNO>NCT00391027</DOCNO>
	<brief_summary>To compare efficacy safety Exubera速 v Lantus速 patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Clinical Trial Comparing Efficacy Safety Exubera速 Lantus速</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Diabetes Mellitus , Type 2 oral agent Age &gt; 30 year Severe Asthma , severe Chronic Obstructive Pulmonary Disease Smoking</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>type 2 diabetes , insulin , glycemic control</keyword>
</DOC>